…
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aktis Oncology, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ (AKTS) focused on developing oncology therapeutics; public information on its pipeline is limited. Long-term growth could be driven by positive clinical trial results, regulatory approvals and strategic partnerships that may support commercialization, offering investors exposure to potential upside from successful development in areas of unmet medical need.
Principal risks include clinical and regulatory setbacks, ongoing need for external financing, competitive pressures in oncology and limited public liquidity, which together could materially affect value.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-12-31 | 2023-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-12-31 | 2023-06-30 |
| Income before tax | -63.73M | -43.98M | -167.94M | -28.64M | -66.00M |
| Minority interest | - | - | - | - | 0.19M |
| Net income | -63.73M | -43.98M | -167.95M | -28.64M | -63.56M |
| Selling general administrative | 12.60M | 11.31M | 35.88M | 7.68M | 29.71M |
| Gross profit | 6.50M | 1.49M | -0.69M | -3.12M | -3.12M |
| Reconciled depreciation | 2.33M | 1.57M | 13.21M | 1.12M | 11.65M |
| Ebit | -74.68M | -52.05M | -165.29M | -34.79M | -63.68M |
| Ebitda | -72.36M | -50.48M | -152.08M | -33.60M | -52.03M |
| Depreciation and amortization | 2.33M | 1.57M | 13.21M | 1.20M | 11.65M |
| Non operating income net other | - | - | - | - | 2.39M |
| Operating income | -74.68M | -52.05M | -109.99M | -34.79M | -66.07M |
| Other operating expenses | 81.18M | 53.54M | 137.38M | 34.79M | 93.19M |
| Interest expense | - | 2.66M | 2.66M | 2.32M | 2.32M |
| Tax provision | - | - | 0.01M | - | -2.45M |
| Interest income | 11.01M | 8.10M | - | 5.38M | - |
| Net interest income | 11.01M | 8.10M | -2.66M | 5.38M | -2.32M |
| Income tax expense | - | 0.01M | 0.01M | -2.45M | -2.45M |
| Total revenue | 6.50M | 1.49M | 27.38M | 27.12M | 27.12M |
| Total operating expenses | 81.18M | 53.54M | 109.30M | 34.79M | 62.95M |
| Cost of revenue | - | 28.07M | 28.07M | 30.24M | 30.24M |
| Total other income expense net | 10.95M | 8.07M | -57.95M | 6.15M | 0.06M |
| Net income from continuing ops | -63.73M | -43.98M | -167.95M | -28.64M | -63.56M |
| Net income applicable to common shares | - | - | - | - | -63.56M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-12-31 | 2023-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-12-31 | 2023-06-30 |
| Total assets | 264.88M | 326.18M | 69.74M | 122.36M | 148.92M |
| Intangible assets | - | 12.56M | 12.56M | 15.24M | 15.24M |
| Other current assets | 3.52M | 3.69M | 4.80M | 2.34M | 4.44M |
| Total liab | 411.03M | 413.98M | 126.83M | 168.66M | 62.68M |
| Total stockholder equity | -146.15M | -87.80M | -57.09M | -46.31M | 86.24M |
| Deferred long term liab | - | - | - | - | 43.35M |
| Other current liab | 9.52M | 6.33M | 69.73M | 3.75M | 13.05M |
| Common stock | - | 0.12M | 0.12M | 0.07M | 0.07M |
| Capital stock | 0.00M | 0.00M | 0.12M | 0.00M | 0.07M |
| Retained earnings | -156.56M | -92.83M | -438.51M | -48.85M | -270.36M |
| Other liab | - | - | - | - | 0.12M |
| Good will | - | 6.51M | 6.51M | 14.56M | 14.56M |
| Other assets | - | - | - | - | 0.07M |
| Cash | 37.78M | 37.16M | 24.45M | 29.51M | 43.10M |
| Total current liabilities | 31.24M | 18.82M | 84.37M | 6.24M | 17.57M |
| Current deferred revenue | 18.66M | 9.28M | 0.13M | 0.10M | 0.10M |
| Net debt | -26.24M | -25.15M | 28.42M | -16.11M | 2.33M |
| Short term debt | 1.31M | 1.30M | 10.51M | 1.53M | 0.44M |
| Short long term debt | - | - | 10.00M | - | - |
| Short long term debt total | 11.55M | 12.01M | 52.86M | 13.40M | 45.43M |
| Other stockholder equity | 10.37M | 4.91M | 381.29M | 2.46M | 356.52M |
| Property plant equipment | - | - | - | - | 57.83M |
| Total current assets | 230.31M | 300.85M | 36.77M | 100.20M | 59.84M |
| Net tangible assets | - | - | - | - | 56.44M |
| Short term investments | 189.00M | 260.01M | - | 68.35M | - |
| Net receivables | - | 5.29M | 5.29M | 4.75M | 4.75M |
| Long term debt | - | - | 41.89M | - | 0.78M |
| Inventory | - | 2.22M | 2.22M | 7.55M | 7.55M |
| Accounts payable | 1.74M | 1.92M | 4.00M | 0.96M | 3.98M |
| Accumulated other comprehensive income | 0.04M | 0.12M | - | 0.08M | - |
| Common stock total equity | - | - | - | - | 0.07M |
| Retained earnings total equity | - | - | - | - | -270.36M |
| Non currrent assets other | 7.33M | 4.46M | 0.07M | 1.23M | 0.07M |
| Non current assets total | 34.58M | 25.33M | 32.97M | 22.15M | 89.07M |
| Capital lease obligations | 11.55M | 12.01M | 0.98M | 13.40M | 1.42M |
| Long term debt total | - | - | - | - | 0.78M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-12-31 | 2023-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-12-31 | 2023-06-30 |
| Investments | 75.55M | -187.54M | -5.99M | -65.12M | -13.88M |
| Change to liabilities | - | - | - | - | 4.01M |
| Total cashflows from investing activities | 65.96M | -190.40M | - | -68.83M | -25.15M |
| Total cash from financing activities | -1.21M | 183.28M | 27.68M | 32.59M | 32.59M |
| Change to operating activities | - | - | - | - | -0.49M |
| Net income | -63.73M | -43.98M | -167.95M | -28.64M | -63.56M |
| Change in cash | 0.62M | 7.65M | -18.66M | -98.83M | -37.38M |
| Begin period cash flow | 38.31M | 30.66M | 43.10M | 129.49M | 80.48M |
| End period cash flow | 38.93M | 38.31M | 24.45M | 30.66M | 43.10M |
| Total cash from operating activities | -64.13M | 14.76M | -40.35M | -30.00M | -44.82M |
| Issuance of capital stock | 0.00M | 185.00M | 12.34M | 0.00M | 32.03M |
| Depreciation | 2.33M | 1.57M | 13.21M | 1.12M | 11.65M |
| Other cashflows from investing activities | - | - | - | 0.06M | 0.12M |
| Change to inventory | - | 5.33M | 5.33M | -3.45M | -3.45M |
| Change to account receivables | 1.03M | -0.86M | 0.64M | -0.26M | -0.08M |
| Sale purchase of stock | - | - | - | - | 32.59M |
| Other cashflows from financing activities | -1.55M | 183.28M | 7.34M | 0.56M | 0.56M |
| Change to netincome | - | - | - | - | 7.20M |
| Capital expenditures | 9.58M | 2.86M | 5.99M | 3.76M | 11.38M |
| Change receivables | - | - | - | - | -0.08M |
| Cash flows other operating | - | - | - | - | -0.76M |
| Cash and cash equivalents changes | - | - | - | - | -37.38M |
| Change in working capital | -3.23M | 58.98M | 65.68M | -0.01M | -0.68M |
| Stock based compensation | 5.13M | 2.26M | 2.85M | 1.48M | 9.41M |
| Other non cash items | -4.62M | -4.07M | 45.87M | -3.95M | 0.75M |
| Free cash flow | -73.71M | 11.90M | -46.34M | -33.77M | -56.21M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| AKTS Aktis Oncology, Inc. Common stock |
0.34 2.09% |
16.62 | - | - | 123.90 | 2.66 | 77.80 |
| NVO Novo Nordisk A/S |
0.98 2.41% |
41.63 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
-4.02 0.74% |
538.60 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
4.28 0.45% |
955.47 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
64.70 7.19% |
965.00 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
| Name | Title | Year Born |
|---|---|---|
| Mr. Jeffrey B. Shealy | Founder, Pres, CEO & Director | 1969 |
| Mr. Kenneth E. Boller | CFO & Corp. Controller | 1971 |
| Mr. David M. Aichele | Exec. VP of Bus. Devel. | 1966 |
| Mr. Andrew Wright | Gen. Counsel & Corp. Sec. | NA |
| Ms. Mary Winters | Exec. VP of Fab & Corp. Operations | NA |
| Mr. Kamran Cheema | Chief Product Officer | NA |
| Mr. Jeffrey B. Shealy | Founder, President, CEO & Director | 1969 |
| Mr. Kenneth E. Boller | CFO & Corporate Controller | 1971 |
| Mr. David M. Aichele | Executive Vice President of Business Development | 1966 |
| Mr. Andrew Wright | General Counsel & Corporate Secretary | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.